Nerve News and Research

RSS

High dose of vitamin D3 safe and effective for obese adolescents

Vitamin D deficiency is common in Americans, and especially in overweight and obese adolescents, according to the National Institutes of Health. University of Missouri researchers have found that providing obese adolescents with a high daily dose of vitamin D3 is safe and effective in improving their vitamin D status.

2 Nov 2011

LDR's ROI-A Oblique ALIF cage receives FDA marketing clearance

LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the ROI-A Oblique ALIF cage. The oblique cage complements its forerunner, the ROI-A ALIF cage, which is designed for direct anterior insertion.

1 Nov 2011

Emotional and psychological traumas may contribute to adult IBS

The psychological and emotional traumas experienced over a lifetime--such as the death of a loved one, divorce, natural disaster, house fire or car accident, physical or mental abuse—may contribute to adult irritable bowel syndrome (IBS), according to the results of a study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Non-invasive rtACS treatment can reduce partial blindness

It has long been thought that blindness after brain lesions is irreversible and that damage to the optic nerves leads to permanent impairments in everyday activities such as reading, driving, and spatial orientation. A new study published in Elsevier's Brain Stimulation suggests that treating such patients with low levels of non-invasive, repetitive, transorbital alternating current stimulation (rtACS) for 10 days significantly reduces visual impairment and markedly improves vision-related quality of life.

1 Nov 2011

Research into new Alzheimer's medication

Several potential drugs for the treatment of Alzheimer's have worked well on mice - but none of them on humans. A leading researcher from the Sahlgrenska Academy at the University of Gothenburg, Sweden, is now launching brand new methods for diagnosing Alzheimer's and monitoring treatment.

1 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Researchers identify FMRP protein as key player in RNA editing

The most common form of heritable cognitive impairment is Fragile X Syndrome, caused by mutation or malfunction of the FMR1 gene. Loss of FMR1 function is also the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others.

31 Oct 2011

Scientists describe how protein acts as courier in cell signaling pathways

Normal development, from fertilized egg to adult organism, depends on each cell receiving proper instructions from its environment. In response to such incoming information, receptors on a cell's surface send signals to the nucleus that tweak gene expression and control cellular function.

28 Oct 2011

Novel technique saves Gulf War veteran's forearm

A plastic surgeon at UT Southwestern Medical Center recently used a novel technique to save the arm of a Gulf War veteran who was rushed to Parkland Memorial Hospital after a horrific accident.

28 Oct 2011

AD risk genes impact Aβ toxicity in neurons

In a development that sheds new light on the pathology of Alzheimer's disease (AD), a team of Whitehead Institute scientists has identified connections between genetic risk factors for the disease and the effects of a peptide toxic to nerve cells in the brains of AD patients.

28 Oct 2011

Apnex Medical's HGNS System receives CE Mark approval for treatment of OSA

Apnex Medical, Inc., has received CE Mark approval for its Hypoglossal Nerve Stimulation System for use by people who suffer from obstructive sleep apnea.

28 Oct 2011

Novel scarless surgery effectively removes skull base tumors

A technique developed by Johns Hopkins surgeons is providing a new route to get to and remove tumors buried at the base of the skull: through the natural hole behind the molars, above the jawbone and beneath the cheekbone.

27 Oct 2011

Medtronic initiates Symplicity System clinical study in treatment-resistant hypertension

Medtronic Inc. announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity Renal Denervation System for treatment-resistant hypertension.

From Medtronic 27 Oct 2011

external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding

NeuroSigma, Inc., a Los Angeles-based medical technology company, announced today that it has signed a contract with the University of California, Los Angeles (UCLA) to fund a Phase I pediatric clinical trial to study the use of non-invasive, external Trigeminal Nerve Stimulation (TNS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

24 Oct 2011

HMS, EPFL to collaborate on 6 pioneering neuroengineering projects

Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.

24 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011

Potential deadly consequences of silicone injections

Reports of adverse events, including death, from silicone injections for cosmetic purposes have been increasing in both medical and consumer literature. In studies presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians (ACCP), in Honolulu, Hawaii, researchers from Louisiana State University Health Sciences Center in New Orleans, Louisiana; Henry Ford Hospital in Detroit, Michigan; and Olive View-UCLA Medical Center in Sylmar, California all reported cases of near-lethal and lethal silicone use.

24 Oct 2011

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech, a member of the Roche Group, today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease.

21 Oct 2011